In this trial, the members of the Mayo Nephrology Collaborative Group provided evidence that patients who received omega-3 fatty acids for 2 years had better preservation of GFR than did a control group. Of interest, the authors did not observe any benefit of their treatment on the level of ...
A single center study with bortezomib is beginning an off-label trial in antibody-mediated rejection (Mayo Clinic, Rochester, MN). Bortezomib is also thought to inhibit NFκB, a key mediator in leukocyte activation. Given the central role of the NFκB pathway in cytokine secretion, adhesion ...
However, there is no such period of stability requirement for other disease sites such as the liver, bone, or adrenal metastases, so why is this requirement necessary for brain metastases? Requiring time periods of CNS stability prior to inclusion on a trial may end up being a back-door way...